Wall Street equity research analysts tracking Humana Inc. (NYSE: HUM) maintain an average twelve-month consensus price target hovering between $384 and $404 USD based on recent forecasts submitted by major financial institutions. Individual target estimates span a conservative lower boundary near $373 up to optimistic peaks exceeding $513, reflecting varying projections concerning Medicare Advantage enrollment trends, medical cost ratio adjustments, and broader regulatory policy developments affecting the health insurance sector.